Adhera Therapeutics, Inc. is an emerging specialty biotech company, which is in the process of evaluating its focus including a return to drug discovery and development. The company is headquartered in Wake Forest, North Carolina. The firm is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The firm's advanced development programs are MLR-1019, a small molecule drug candidate being developed for PD, and MLR-1023, being developed to treat Type 1 diabetes. MLR-1019 is a highly selective dopamine re-uptake inhibitor for treating the dyskinesias associated with chronic dopamine precursor levodopa (L-DOPA) treatment in PD patients. MLR-1019 is a highly selective dopamine reuptake transporter (DAT) inhibitor used for the treatment of type 1 diabetes, non-alcoholic steatohepatitis, and pulmonary inflammation. The company utilizes a virtual drug development model, where contract research organizations (CROs) are employed to undertake certain drug discovery and development services on the Company’s behalf and under its direct supervision.

Industry: Pharmaceutical Preparations Peers: Ayala Pharmaceuticals, Inc. RenovaCare, Inc. U.S. Stem Cell, Inc. Burzynski Research Institute Inc Tenax Therapeutics Inc